Back to dashboard
CommercialCoverageMedium impact

Bioimpedance Devices for Detection and Management of Lymphedema

Blue Cross & Blue Shield of Mississippi·MS · Oncology, Plastic Surgery, Physical Therapy +2 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS Mississippi now covers bioimpedance spectroscopy devices (like SOZO and MoistureMeterD) for lymphedema diagnosis and surveillance in specific clinical scenarios, including asymptomatic patients at risk and those not responding to conservative therapy. The policy establishes medical necessity criteria for when these diagnostic tests will be covered.

Action Required

Action needed
Immediately: Review current lymphedema patients to identify candidates for bioimpedance spectroscopy coverage. Update billing procedures to ensure proper documentation of medical necessity criteria (asymptomatic with lymphatic system history, failed conservative therapy, or surveillance needs). Train billing staff on the specific clinical scenarios that qualify for coverage versus investigational use.